1 / 3

Staph Infection Medication

There is a way to end the cycle of frustrating and excessive expense when your antibiotic therapy works short-term wonders, but results in chronic problems soon after treatment is terminated. Delmont's Staphage Lysate (SPL)® has been shown to be a highly effective immunotherapeutic when used concurrently with or as a follow-up to antibiotics in the treatment of idiopathic recurrent canine pyoderma<br>

delmontlaboratories
Download Presentation

Staph Infection Medication

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Staph Infection Medication There is a way to end the cycle of frustrating and excessive expense when your antibiotic therapy works short-term wonders, but results in chronic problems soon after treatment is terminated. Delmont's Staphage Lysate (SPL) ® has been shown to be a highly effective immunotherapeutic when used concurrently with or as a follow-up to antibiotics in the treatment of idiopathic recurrent canine pyoderma. Documented Efficacy In addition to widespread use in veterinary practices, SPL's value has been recorded in controlled studies. Significantly, use of SPL represents a proven way to avoid extended use of antibiotics. The Professional Solution With SPL, your practice gains clients' appreciation for having controlled the dog's pruritic lesions on a long-term basis. Clients also appreciate the saving in time and money required by indefinite antibiotic regimens. SPL Information

  2. SPL® is a highly effective bacterial antigen licensed for the treatment of idiopathic canine pyoderma. It is the only staphylococcal product of its kind approved for canine use. Our double blinded study demonstrated a 77% efficacy rate in pyoderma caused by Staphylococcus intermedius. The most important predictor of successful SPL therapy is the selection of appropriate cases. The dog should have a history of recurrent, idiopathic pyoderma. Its disease should be responsive to antibiotics. All underlying causes should be ruled out (i.e., demodicosis, flea allergy dermatitis, food allergy and hypothyroidism). Recurrent Staphylococcal Infections A major concern of veterinary dermatologists has been the recalcitrant nature of recurrent pyoderma. Too often - shortly upon the conclusion of an antibiotic treatment modality - staphylococcal skin infection recurs. Traditionally, three treatment programs are utilized by veterinary dermatologists: (1) antibiotics; (2) benzyl peroxide shampoos for the elimination of the staph; and (3) immune-therapy with products such as Staphylococcus Aureus Phage Lysate. Immunostimulants which are frequently used to treat pyoderma have a common mechanism of enhancing cellular immunity. Cellular immune mechanisms generally involve the activation of phagocytes and the stimulation of T cells. Immunological Research Current immunological research studies indicate that one set of helper T cells designated TH1 is important for providing cell-mediated resistance to infection while TH2 cells provide a humoral response and suppress cell-mediated responses. These T cells produce distinctly different regulatory cytokines with TH2 cells producing IL-4, IL-5, and IL-l0. 1L-4 has been reported to block IL-2 dependent proliferation of T cells and can block macrophage nitric oxide generation, which is necessary for killing intracellular parasites.1

  3. Recent research by Delmont Laboratories indicates that those cytokines typical of TH1 cells, IL-2 and interferon gamma, are induced in peripheral blood monocytic cells by Staphage Lysate (SPL)®. These results were reported at the 12th Annual European Immunology Meeting in Barcelona, Spain, June 1994. TH1 cells have been found to be vital to the production of cell-mediated resistance to bacterial infections and particularly important for resistance to chronic skin infections. Our original veterinary canine pyoderma double blinded clinical study saw an improvement in approximately 75% of the cases treated with Staphage Lysate (SPL)®. Those results are consistent with the findings of ongoing surveys of new Delmont Laboratories' veterinary customers in their treatment of canine pyoderma. Human Clinical Study Delmont Laboratories has recently sponsored a human clinical study on the use of Staphage Lysate (SPL)® to treat various staphylococcal infections, predominantly those affecting the skin. During therapy, the number of active peripheral blood phagocytes increased as the symptoms decreased. A total of 99 patients were treated by six different physicians. The conditions treated included impetigo, recurrent furunculosis, atopic eczema, osteomyelitis, otitis media, and hidradenitis suppurativa.2 For example - in cases of staphylococcal impetigo - complete clearing of the infection was observed after an 8 - 12 week period of treatment. These patients had a substantial increase in the number of active peripheral phagocytes as measured by uptake of Candida albicans. The course of therapy and the time required to show improvement were similar to that found using Staphage Lysate (SPL)® in cases of canine pyoderma. For more information please visit http://www.delmont.com

More Related